United States Genomics Market PPT: Growth, Outlook, Demand, Keyplayer Analysis and Opportunity 2024-32
                     United States 
Genomics Market 
Research and Forecast 
Report 2024-2032
Format: PDF+EXCEL
© 2023 IMARC All Rights Reserved 
About IMARC Group
IMARC Group is  a g lobal  management  consul t ing f i rm that  he lps the wor ld ’s  most  ambi t ious 
changemakers  to create a las t ing impact .  Across the s ix  major  cont inents  and 100+ count r ies ,  we 
work a longside our  bus iness par tners  as one team wi th  a common ambi t ion to achieve unparal le led 
resul ts ,  gain a compet i t ive edge,  and t ransform indust r ies .  IMARC Group excels  in  unders tanding 
i ts  c l ients ’  bus iness pr ior i t ies  and del iver ing ta i lored solut ions that  dr ive meaningfu l  outcomes.  Our 
c l ient  base spans over  3,000 organizat ions in  the pr ivate,  publ ic ,  and soc ia l  sectors ,  ranging f rom 
high-growth s tar tups to For tune 500 companies.
We prov ide a comprehensive sui te of  market  entry  and expansion serv ices.  Our of fer ings inc lude 
thorough market  assessment ,  feas ib i l i ty  s tudies,  company incorporat ion ass is tance,  fac tory  setup 
suppor t ,  regulatory  approvals and l icens ing navigat ion,  branding,  market ing and sales st rategies,  
compet i t ive landscape and benchmark ing analyses,  pr ic ing and cost  research,  and procurement  
research.  These serv ices are des igned to ass is t  companies in  evaluat ing market  oppor tuni t ies ,  
set t ing up new ent i t ies ,  navigat ing regulatory landscapes,  boost ing brand v is ib i l i ty ,  analyz ing 
compet i tors,  and opt imiz ing procurement  s t rategies.
A c c o r d i n g  t o  t h e  l a t e s t  r e p o r t  b y  I M A R C  G r o u p ,  t i t l e d  " U n i t e d  S t a t e s  G e n o m i c s  M a r k e t :  I n d u s t r y  
T r e n d s ,  S h a r e ,  S i z e ,  G r o w t h ,  O p p o r t u n i t y  a n d  F o r e c a s t  2 0 2 4 - 2 0 3 2 , "  t h e  U n i t e d  S t a t e s  g e n o m i c s  
m a r k e t  s i z e  i s  p r o j e c t e d  t o  e x h i b i t  a  g r o w t h  r a t e  ( C A G R )  o f  1 9 . 6 0 %  d u r i n g   2 0 2 4 - 2 0 3 2  .
O v e r  t h e  p a s t  t w o  d e c a d e s ,  t h e  d e v e l o p m e n t  o f  n e x t - g e n e r a t i o n  s e q u e n c i n g  ( N G S )  t e c h n o l o g i e s  h a s  
r e v o l u t i o n i z e d  t h e  f i e l d  o f  g e n o m i c s  b y  e n a b l i n g  t h e  r a p i d ,  a c c u r a t e ,  a n d  c o s t - e f f e c t i v e  s e q u e n c i n g  
Report o f  e n t i r e  g e n o m e s .  T h e s e  a d v a n c e m e n t s  h a v e  s i g n i f i c a n t l y  l o w e r e d  t h e  c o s t  o f  s e q u e n c i n g  a  h u m a n  g e n o m e  f r o m  b i l l i o n s  o f  d o l l a r s  t o  l e s s  t h a n  $ 1 , 0 0 0 ,  m a k i n g  g e n o m i c  d a t a  m o r e  a c c e s s i b l e  t o  
r e s e a r c h e r s ,  h e a l t h c a r e  p r o v i d e r s ,  a n d  p a t i e n t s .  T h i s  d e m o c r a t i z a t i o n  o f  g e n o m i c  i n f o r m a t i o n  h a s  
s p u r r e d  a  s u r g e  i n  g e n o m i c  r e s e a r c h ,  p e r s o n a l i z e d  m e d i c i n e ,  a n d  c o n s u m e r  g e n o m i c s .  R e s e a r c h e r s  
Highlight and c a n  n o w  c o n d u c t  l a r g e - s c a l e  g e n o m i c  s t u d i e s ,  l e a d i n g  t o  t h e  d i s c o v e r y  o f  n e w  g e n e t i c  m a r k e r s  a n d  
t h e  d e v e l o p m e n t  o f  t a r g e t e d  t h e r a p i e s  f o r  v a r i o u s  d i s e a s e s .  I n  t h e  c l i n i c a l  s e t t i n g ,  a f f o r d a b l e  
g e n o m i c  s e q u e n c i n g  h a s  p a v e d  t h e  w a y  f o r  p r e c i s i o n  m e d i c i n e ,  w h e r e  t r e a t m e n t s  a n d  p r e v e n t i v e  
Description s t r a t e g i e s  a r e  t a i l o r e d  t o  t h e  i n d i v i d u a l  g e n e t i c  p r o f i l e s  o f  p a t i e n t s ,  i m p r o v i n g  o u t c o m e s ,  a n d  r e d u c i n g  a d v e r s e  e f f e c t s .  A n o t h e r  c r u c i a l  f a c t o r  d r i v i n g  t h e  U n i t e d  S t a t e s  g e n o m i c s  m a r k e t  i s  t h e  
g r o w i n g  i n t e g r a t i o n  o f  g e n o m i c s  i n t o  h e a l t h c a r e  a n d  t h e  i n c r e a s i n g  d e m a n d  f o r  p e r s o n a l i z e d  
m e d i c i n e .  T h e  r i s e  o f  p r e c i s i o n  m e d i c i n e ,  w h i c h  f o c u s e s  o n  c u s t o m i z i n g  h e a l t h c a r e  b a s e d  o n  a n  
i n d i v i d u a l ’ s  g e n e t i c  m a k e u p ,  l i f e s t y l e ,  a n d  e n v i r o n m e n t ,  i s  f u n d a m e n t a l l y  a l t e r i n g  t h e  l a n d s c a p e  o f  
m e d i c a l  t r e a t m e n t .  
R e q u e s t  f o r  a  P D F  s a m p l e  o f  t h i s  r e p o r t :  
h t t p s : / / w w w . i m a r c g r o u p . c o m / u n i t e d - s t a t e s - g e n o m i c s - m a r k e t / r e q u e s t s a m p l e
Report Description
Uni ted  S ta tes  Genomi cs  Market  T rends:
The  inc reas ing  adopt i on  o f  genomics  in  hea l t hca re  i s  suppor t ed  by  s ign i f i can t  inves t ment s  f rom bo th  t he  pub l i c  and  
pr i va t e  sec t o r s .  The  Na t iona l  I ns t i t u t es  o f  Hea l th  (NI H)  and o the r  gove rnment  agenc ies  have  launched la rge -sca le  
in i t i a t i ves ,  such  as  the  A l l  o f  Us  Research  P rogram,  a imed  a t  ga the r ing  gene t i c  da t a  f rom d iverse  popu la t ions  to  
advance  ou r  unders t and ing  o f  hea l t h  and  d i sease .  These  p rograms no t  on ly  d r i ve  sc ien t i f i c  d i scove ry  bu t  a lso  bu i ld  
in f ras t ruc tu re  and  c rea te  da t abases  tha t  f ac i l i t a te  fu r the r  r esearch  and c l in i ca l  app l i ca t ions .  
I n  t he  p r i va te  sec t o r ,  pha rmaceu t i ca l  and  b io techno logy  compan ies  a re  inves t i ng  heav i l y  i n  genomics  t o  acce le ra te  
d rug  d iscovery  and  deve lopmen t .  Co l labo ra t ions  be t ween indus t ry ,  academia ,  and  hea l thca re  p rov iders  a re  f os te r ing  
innova t i on  and t rans la t i ng  genomic  research  in t o  c l i n i ca l  p rac t i ce .  Regu la to ry  suppor t  and  t he  es tab l i shment  o f  
e t h ica l  gu ide l ines  a lso  p lay  a  v i t a l  r o le  in  d r i v i ng  the  genomics  m arke t .  The U. S .  Food  and  Drug  Adm in i s t ra t ion  (FDA)  
and o ther  r egu la t o r y  bod ies  a re  work ing  t o  c rea te  f r ameworks  tha t  ensure  the  sa fe  and  e f f ec t i ve  use  o f  genomic  
techno log ies  i n  hea l thcare .
Vi ew Report  TOC,  F igures and  Tab les :  h t tps: / / www. i marcgroup .com/un i ted -states -genomics-market
Component Insights:
•  Products
o Instruments and Software
o Consumables and Reagents
•  Services
o Core Genomics Services
Report o NGS-Based Services
o Biomarker Translat ion Services
Segmentation o Computat ional Services
o Others
Technology Insights:
• Sequencing
• Microarray
• Polymerase Chain React ion
• Nucleic Acid Extraction and Purifi cation
• Others
Application Insights:
• Functional  Genomics
• Epigenomics
Report 
• Biomarkers Discovery
Segmentation • Pathway Analysis
• Others
End User Insights:
• Research Centers
• Hospitals and Cl inics
• Pharmaceutical  and Biotechnology Companies
• Others
Regional Insights:
• Northeast 
•
Report Midwest 
• South 
Segmentation • West
How has the United States genomics market 
performed so far and how will it perform in the 
coming years?
What has been the impact of COVID-19 on the 
United States genomics market?
Key 
Questions What is the breakup of the United States genomics market on the basis of component?
Answered in 
What is the breakup of the United States genomics 
the Report market on the basis of technology?
What is the breakup of the United States genomics 
market on the basis of application?
What is the breakup of the United States genomics 
market on the basis of end user?
What are the various stages in the value chain of 
the United States genomics market? 
What are the key driving factors and challenges in 
the United States genomics?
Key What is the structure of the United States 
genomics market and who are the key players?
Questions 
Answered in What is the degree of competition in the United States genomics market?
the Report
1     P r e f a c e
2     S c o p e  a n d  M e t h o d o l o g y
    2 . 1     O b j e c t i v e s  o f  t h e  S t u d y
    2 . 2     S t a k e h o l d e r s
    2 . 3     D a t a  S o u r c e s
        2 . 3 . 1     P r i m a r y  S o u r c e s
        2 . 3 . 2     S e c o n d a r y  S o u r c e s
    2 . 4     M a r k e t  E s t i m a t i o n
Table of         2 . 4 . 1     B o t t o m - U p  A p p r o a c h        2 . 4 . 2     T o p - D o w n  A p p r o a c h
    2 . 5     F o r e c a s t i n g  M e t h o d o l o g y
3     E x e c u t i v e  S u m m a r y
4    U n i t e d  S t a t e s  G e n o m i c s  M a r k e t  -  I n t r o d u c t i o n
Contents     4 . 1     O v e r v i e w    4 . 2     M a r k e t  D y n a m i c s
    4 . 3     I n d u s t r y  T r e n d s
    4 . 4     C o m p e t i t i v e  I n t e l l i g e n c e
5    U n i t e d  S t a t e s  G e n o m i c s  M a r k e t  L a n d s c a p e
    5 . 1     H i s t o r i c a l  a n d  C u r r e n t  M a r k e t  T r e n d s  ( 2 0 1 8 - 2 0 2 3 )
    5 . 2     M a r k e t  F o r e c a s t  ( 2 0 2 4 - 2 0 3 2 )
6    U n i t e d  S t a t e s  G e n o m i c s  M a r k e t  -  B r e a k u p  b y  C o m p o n e n t
    6 . 1     P r o d u c t s
        6 . 1 . 1  O v e r v i e w
        6 . 1 . 2  H i s t o r i c a l  a n d  C u r r e n t  M a r k e t  T r e n d s  ( 2 0 1 8 - 2 0 2 3 )
        6 . 1 . 3  M a r k e t  S e g m e n t a t i o n
           6 . 1 . 3 . 1  I n s t r u m e n t s  a n d  S o f t w a r e
           6 . 1 . 3 . 2  C o n s u m a b l e s  a n d  R e a g e n t s
        6 . 1 . 4  M a r k e t  F o r e c a s t  ( 2 0 2 4 - 2 0 3 2 )
       
   6 . 2     S e r v i c e s
        6 . 2 .1  O ve r v i e w
        6 . 2 .2  H i s t o r i c a l  a nd  C u r r e n t  Ma r k e t  T r e n ds  ( 2 0 18 - 2 0 2 3 )
        6 . 2 .3  M a rk e t  S e g m en t a t i o n
           6 . 2 . 3 . 1  C o r e  G e n om i c s  S e r v i c e s
           6 . 2 . 3 . 2  N G S -B a s e d  S e r v i c es
           6 . 2 . 3 . 3  B i o m ar k e r  T r a n s l a t i o n  S e r v i c e s
           6 . 2 . 3 . 4  C o m pu t a t i on a l  S e rv i c e s
           6 . 2 . 3 . 5  O t h e r s
        6 . 2 .4  M a rk e t  F o r e c a s t  ( 2 02 4 - 2 0 32 )
7    U n i t e d  S ta t e s  G e n o m i c s  M a r k e t  -  B r e a k u p  b y  T e c h n o lo g y
Table of     7 . 1     S e q u en c i n g        7 . 1 .1  O ve r v i e w
        7 . 1 .2  H i s t o r i c a l  a nd  C u r r e n t  Ma r k e t  T r e n ds  ( 2 0 18 - 2 0 2 3 )
Contents         7 . 1 .3  M a rk e t  F o r e c a s t  ( 2 02 4 - 2 0 32 )    7 . 2     M i c r o a r r a y
        7 . 2 .1  O ve r v i e w
        7 . 2 .2  H i s t o r i c a l  a nd  C u r r e n t  Ma r k e t  T r e n ds  ( 2 0 18 - 2 0 2 3 )
        7 . 2 .3  M a rk e t  F o r e c a s t  ( 2 02 4 - 2 0 32 )
    7 . 3     P o l y m er a s e  C h a i n  R e a c t i o n
        7 . 3 .1  O ve r v i e w
        7 . 3 .2  H i s t o r i c a l  a nd  C u r r e n t  Ma r k e t  T r e n ds  ( 2 0 18 - 2 0 2 3 )
        7 . 3 .3  M a rk e t  F o r e c a s t  ( 2 02 4 - 2 0 32 )
    7 . 4     N u c l e i c  A c i d  E x t r a c t i o n  a n d  P u r i f i c a t i o n
        7 . 4 .1  O ve r v i e w
        7 . 4 .2  H i s t o r i c a l  a nd  C u r r e n t  Ma r k e t  T r e n ds  ( 2 0 18 - 2 0 2 3 )
        7 . 4 .3  M a rk e t  F o r e c a s t  ( 2 02 4 - 2 0 32 )
F o r  m o r e  i n f o r m a t i o n ,  v i s i t :  
ht tps : / /www. imarcgroup .com/un i ted -s ta t es -genomics -mar
ket / toc
Partial List of Clients
Partial List of Clients
Disclaimer
© 2024  IMARC Al l  R ights  Reserved 
Th is  Pub l i ca t ion  and  a l l  i t ’ s  con ten ts  un less  o therw ise  men t i oned  a re  copy r i gh ted  in  the  name o f  
I n t e rna t i ona l  Marke t  Ana lys i s  Research  and  Consu l t ing  ( IMARC) .  No  pa r t  o f  t h i s  pub l i ca t ion  may  be  
rep roduced ,  repackaged ,  red i s t r i bu ted  o r  res o ld  i n  who le  o r  i n  any  pa r t .  The  pub l i ca t ion  may  a l so  
no t  be  used  i n  any  f o rm o r  by  and means  g raph i c  e lec t ron ic  o r  mechan ic a l ,  i nc lud ing  pho tocopy ing ,  
reco rd ing ,  t ap ing  o r  by  i n fo rmat i on  s to rage  o r  re t r ieva l ,  o r  by  any  o the r  f o rm,  w i t hou t  the  exp ress  
c ons en t  o f  I n t e rna t iona l  Marke t  Ana lys i s  Research  and  Consu l t i ng  ( IMARC) .
Disc la imer :  Al l  con ten ts  and  da ta  o f  t h i s  pub l i c a t i on ,  i nc lud ing  fo recas t s ,  da ta  ana lys i s  and  op in ion  
have  been  based  on  in f o rmat ion  and  sources  be l ieved  to  be  accu ra te  and  re l iab le  a t  t he  t ime  o f  
pub l i sh ing .  In t e rna t i ona l  Ma rke t  Ana l ys is  Research  and  Consu l t ing  makes  no  rep resen ta t ion  o f  
war ran t y  o f  any  k ind  as  to  t he  acc u racy  o r  comp le teness  o f  any  I n fo rmat i on  p rov ided .  IMARC 
accep ts  no  l i ab i l i t y  wha tsoever  f o r  any  los s  o r  damage  resu l t i ng  f rom op in ion ,  e r ro rs  o r  
i naccu rac ies  i f  any  f ound  th is  pub l i ca t ion .
IMARC,  IMARC Group  and  G loba l  Therapy  I ns igh t  Ser i es  a re  reg is t e red  t rademarks  o f  I n te rna t iona l  
Marke t  Ana lys i s  Research  and  Consu l t ing .  A l l  o the r  t rademarks  used  i n  th i s  pub l i ca t i on  a re  
reg i s te red  t rademarks  o f  t he i r  r espec t i ve  compan ies .
Contact Us
Visit us at :
https://www.imarcgroup.com
+1-631-791-1145
[email protected]
Stay With Us: